Mast cell activation disorder masquerading as pure red cell aplasia

Sawada K, Fujishama N, Hirokawa M. Acquired pure red cell aplasia: updated review of treatment. Br J Haematol. 2008;142(4):505–14. Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. France: IARC; 2008. Roberts LJ, Anthony LB, Oates JA. Disorders of vasodilator hormones: carcinoid syndrome and mastocytosis. In: Wilson JD, Foster DW, Kronenberg HM, et al., editors. Williams textbook of endocrinology. 9th ed. Philadelphia: W. B. Saunders Company; 1998. p. 1718–32. Ibelgaufts H. Mast cells. In: COPE: cytokines and cells online pathfinder encyclopaedia. 2010. http://www.copewithcytokines.de/cope.cgi?key=mast%20cells. Accessed 14 Mar 2010. Akin C, Metcalfe DD. The biology of Kit in disease and the application of pharmacogenetics. J Allergy Clin Immunol. 2004;114(1):13–9. Molderings GJ, Kolck UW, Scheurlen C, Brüss M, Homan J, Von Kügelgen I. Multiple novel alterations in Kit tyrosine kinase in patients with gastrointestinally pronounced systemic mast cell activation disorder. Scand J Gastroenterol. 2007;42(9):1045–53. Pardanani A, Elliott M, Reeder T, et al. Imatinib for systemic mast-cell disease. Lancet. 2003;362(9383):535–6.